Allan J.W. Lui

Acquired <i>ALK</i> and <i>RET</i> Gene Fusions as Mechanisms of Resistance to Osimertinib in <i>EGFR</i> -Mutant Lung Cancers

Michael Offin, Romel Somwar, Natasha Rekhtman et al. · JCO Precision Oncology · 2018 · 92 citations · Full text

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by <i>ROS1</i> Fusions

Hiroki Sato, Adam J. Schoenfeld, Evan Siau et al. · Clinical Cancer Research · 2020 · 48 citations · Full text

The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic <i>NRG1</i> Fusions

Igor Odintsov, Allan J.W. Lui, Whitney J. Sisso et al. · Clinical Cancer Research · 2021 · 48 citations · Full text

Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers

Igor Odintsov, Marissa S. Mattar, Allan J.W. Lui et al. · Journal of Thoracic Oncology · 2021 · 30 citations · Full text

Medicine, Therapeutic Strategies, Mtor Signaling +9

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

Isao Miyazaki, Igor Odintsov, Keiji Ishida et al. · Nature Cancer · 2023 · 30 citations · Full text